CNS International Prognostic Index (CNS-IPI) for DLBCL
Predicts 2-year risk of CNS relapse in Diffuse Large B-Cell Lymphoma (DLBCL) treated with R-CHOP.
Score interpretation
CNS-IPI 0–1: ~0.6% 2-year CNS relapse risk.
→ Standard R-CHOP. CNS prophylaxis not routinely indicated.
CNS-IPI 2–3: ~3.4% 2-year CNS relapse risk.
→ Consider CNS prophylaxis. Discuss with treating haematologist. Baseline MRI brain.
CNS-IPI 4–6: ~10.2% 2-year CNS relapse risk.
→ CNS prophylaxis strongly recommended (IT methotrexate or high-dose IV methotrexate). Baseline MRI brain mandatory.
Interpretation bands for the CNS-IPI. Apply clinical judgement and local guidance.
References
- Schmitz N et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2016;34(26):3150-3156.
Related
Curated clinical cross-links plus same-class fallbacks.
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- Ann Arbor Staging for Lymphoma · Lymphoma
- NCCN-IPI for Diffuse Large B-Cell Lymphoma · Lymphoma
- MALT Lymphoma International Prognostic Index (MALT-IPI) · Lymphoma
- Mantle Cell Lymphoma International Prognostic Index (MIPI) · Lymphoma
- R-IPI — Revised International Prognostic Index for DLBCL · Lymphoma
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.